Product Image

Contributor Information

  • Name Christopher Tape ; Gillian Murphy
  • Institute Cancer Research UK, Cambridge Institute, England
  • Primary citation Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-5583. PMID: 21415364.

Tool Details

  • Tool name: Anti-TACE [D1 (A12)] rAb
  • Alternate names: Anti-TACE [D1 (A12)]
  • Clone: D1 (A12)
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Recombinant
  • Conjugate: Biotin
  • Reactivity: Human
  • Host: Human
  • Cancer type: Neurological cancer; Genitourinary cancer; Liver cancer; Lung
  • Molecular weight of the target: 93.02/ 91.12/ 68.22 kDa (prepro-/pro-/mature form) calculated
  • Application: Fn
  • Description: Anti-TACE [D1 (A12)] is a human recombinant antibody. This antibody displays inhibitory behaviour to TNF-alpha converting enzyme (TACE). TACE is a membrane-bound metalloprotease (ADAM17) proved capable of cleaving a variety of pathologically significant substrates. TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.

    D1(A12) binds a cross-domain epitope. D1(A12) is the first ADAM inhibitor to show an affinity preference for the complete TACE ectodomain over the isolated catalytic domain.

    This antibody is a selective TACE antagonist and provides a unique alternative to small molecule metalloprotease inhibition. This antibody allows the study of the individual pathological impact of TACE activity.
  • Immunogen: Recombinant human ADAM17 (TACE) ectodomain tagged to biotin.
  • Isotype: IgG1
  • Research area: Cancer; Cell signaling and signal transduction; Metabolism; Neurobiology; Stem cell biology

  • For Research Use Only

Target Details

  • Target: TACE (ADAM17)
  • Target molecular weight: 93.02/ 91.12/ 68.22 kDa (prepro-/pro-/mature form) calculated
  • Target background: TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule metalloprotease inhibition.

Application Details

  • Application: Fn

Handling

  • Format: Liquid
  • Concentration: 5.9 mg/ml
  • Storage buffer: PBS
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

Documentation

References

  •   Caiazza et al. 2015. Br J Cancer. 112(12):1895-1903. PMID: 26010411.
  •   Issuree et al. 2013. J Clin Invest. 123(2):928-932. PMID: 23348744.
  •   Richards et al. 2012. PLoS One. 7(7):e40597. PMID: 22792380.
  •   Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-5583. PMID: 21415364.